455 related articles for article (PubMed ID: 21996585)
1. Features of the reversible sensitivity-resistance transition in PI3K/PTEN/AKT signalling network after HER2 inhibition.
Goltsov A; Faratian D; Langdon SP; Mullen P; Harrison DJ; Bown J
Cell Signal; 2012 Feb; 24(2):493-504. PubMed ID: 21996585
[TBL] [Abstract][Full Text] [Related]
2. PI3K-p110α mediates resistance to HER2-targeted therapy in HER2+, PTEN-deficient breast cancers.
Wang Q; Liu P; Spangle JM; Von T; Roberts TM; Lin NU; Krop IE; Winer EP; Zhao JJ
Oncogene; 2016 Jul; 35(27):3607-12. PubMed ID: 26500061
[TBL] [Abstract][Full Text] [Related]
3. Frequent mutational activation of the PI3K-AKT pathway in trastuzumab-resistant breast cancer.
Chandarlapaty S; Sakr RA; Giri D; Patil S; Heguy A; Morrow M; Modi S; Norton L; Rosen N; Hudis C; King TA
Clin Cancer Res; 2012 Dec; 18(24):6784-91. PubMed ID: 23092874
[TBL] [Abstract][Full Text] [Related]
4. Increased signalling of EGFR and IGF1R, and deregulation of PTEN/PI3K/Akt pathway are related with trastuzumab resistance in HER2 breast carcinomas.
Gallardo A; Lerma E; Escuin D; Tibau A; Muñoz J; Ojeda B; Barnadas A; Adrover E; Sánchez-Tejada L; Giner D; Ortiz-Martínez F; Peiró G
Br J Cancer; 2012 Apr; 106(8):1367-73. PubMed ID: 22454081
[TBL] [Abstract][Full Text] [Related]
5. HER2 expression and PI3K-Akt pathway alterations in gastric cancer.
Sukawa Y; Yamamoto H; Nosho K; Ito M; Igarashi H; Naito T; Mitsuhashi K; Matsunaga Y; Takahashi T; Mikami M; Adachi Y; Suzuki H; Shinomura Y
Digestion; 2014; 89(1):12-7. PubMed ID: 24458107
[TBL] [Abstract][Full Text] [Related]
6. PTEN expression controls cellular response to cetuximab by mediating PI3K/AKT and RAS/RAF/MAPK downstream signaling in KRAS wild-type, hormone refractory prostate cancer cells.
Bouali S; Chrétien AS; Ramacci C; Rouyer M; Becuwe P; Merlin JL
Oncol Rep; 2009 Mar; 21(3):731-5. PubMed ID: 19212633
[TBL] [Abstract][Full Text] [Related]
7. Frequent PTEN genomic alterations and activated phosphatidylinositol 3-kinase pathway in basal-like breast cancer cells.
Marty B; Maire V; Gravier E; Rigaill G; Vincent-Salomon A; Kappler M; Lebigot I; Djelti F; Tourdès A; Gestraud P; Hupé P; Barillot E; Cruzalegui F; Tucker GC; Stern MH; Thiery JP; Hickman JA; Dubois T
Breast Cancer Res; 2008; 10(6):R101. PubMed ID: 19055754
[TBL] [Abstract][Full Text] [Related]
8. A preclinical evaluation of the PI3K alpha/delta dominant inhibitor BAY 80-6946 in HER2-positive breast cancer models with acquired resistance to the HER2-targeted therapies trastuzumab and lapatinib.
Elster N; Cremona M; Morgan C; Toomey S; Carr A; O'Grady A; Hennessy BT; Eustace AJ
Breast Cancer Res Treat; 2015 Jan; 149(2):373-83. PubMed ID: 25528022
[TBL] [Abstract][Full Text] [Related]
9. PTEN, PIK3CA, p-AKT, and p-p70S6K status: association with trastuzumab response and survival in patients with HER2-positive metastatic breast cancer.
Esteva FJ; Guo H; Zhang S; Santa-Maria C; Stone S; Lanchbury JS; Sahin AA; Hortobagyi GN; Yu D
Am J Pathol; 2010 Oct; 177(4):1647-56. PubMed ID: 20813970
[TBL] [Abstract][Full Text] [Related]
10. Sensitivity to targeted therapy differs between HER2-amplified breast cancer cells harboring kinase and helical domain mutations in PIK3CA.
Garay JP; Smith R; Devlin K; Hollern DP; Liby T; Liu M; Boddapati S; Watson SS; Esch A; Zheng T; Thompson W; Babcock D; Kwon S; Chin K; Heiser L; Gray JW; Korkola JE
Breast Cancer Res; 2021 Aug; 23(1):81. PubMed ID: 34344439
[TBL] [Abstract][Full Text] [Related]
11. Direct inhibition of PI3K in combination with dual HER2 inhibitors is required for optimal antitumor activity in HER2+ breast cancer cells.
Rexer BN; Chanthaphaychith S; Dahlman K; Arteaga CL
Breast Cancer Res; 2014 Jan; 16(1):R9. PubMed ID: 24451154
[TBL] [Abstract][Full Text] [Related]
12. Decoupling of the PI3K Pathway via Mutation Necessitates Combinatorial Treatment in HER2+ Breast Cancer.
Korkola JE; Collisson EA; Heiser M; Oates C; Bayani N; Itani S; Esch A; Thompson W; Griffith OL; Wang NJ; Kuo WL; Cooper B; Billig J; Ziyad S; Hung JL; Jakkula L; Feiler H; Lu Y; Mills GB; Spellman PT; Tomlin C; Mukherjee S; Gray JW
PLoS One; 2015; 10(7):e0133219. PubMed ID: 26181325
[TBL] [Abstract][Full Text] [Related]
13. Compensatory effects in the PI3K/PTEN/AKT signaling network following receptor tyrosine kinase inhibition.
Goltsov A; Faratian D; Langdon SP; Bown J; Goryanin I; Harrison DJ
Cell Signal; 2011 Feb; 23(2):407-16. PubMed ID: 20951800
[TBL] [Abstract][Full Text] [Related]
14. Combination treatment with a PI3K/Akt/mTOR pathway inhibitor overcomes resistance to anti-HER2 therapy in PIK3CA-mutant HER2-positive breast cancer cells.
Fujimoto Y; Morita TY; Ohashi A; Haeno H; Hakozaki Y; Fujii M; Kashima Y; Kobayashi SS; Mukohara T
Sci Rep; 2020 Dec; 10(1):21762. PubMed ID: 33303839
[TBL] [Abstract][Full Text] [Related]
15. Evaluation of the association of PIK3CA mutations and PTEN loss with efficacy of trastuzumab therapy in metastatic breast cancer.
Razis E; Bobos M; Kotoula V; Eleftheraki AG; Kalofonos HP; Pavlakis K; Papakostas P; Aravantinos G; Rigakos G; Efstratiou I; Petraki K; Bafaloukos D; Kostopoulos I; Pectasides D; Kalogeras KT; Skarlos D; Fountzilas G
Breast Cancer Res Treat; 2011 Jul; 128(2):447-56. PubMed ID: 21594665
[TBL] [Abstract][Full Text] [Related]
16. Estrogen receptor β represses Akt signaling in breast cancer cells via downregulation of HER2/HER3 and upregulation of PTEN: implications for tamoxifen sensitivity.
Lindberg K; Helguero LA; Omoto Y; Gustafsson JÅ; Haldosén LA
Breast Cancer Res; 2011 Apr; 13(2):R43. PubMed ID: 21492444
[TBL] [Abstract][Full Text] [Related]
17. Mechanism of resistance to endocrine therapy in breast cancer: the important role of PI3K/Akt/mTOR in estrogen receptor-positive, HER2-negative breast cancer.
Araki K; Miyoshi Y
Breast Cancer; 2018 Jul; 25(4):392-401. PubMed ID: 29086897
[TBL] [Abstract][Full Text] [Related]
18. The association of PI3 kinase signaling and chemoresistance in advanced ovarian cancer.
Carden CP; Stewart A; Thavasu P; Kipps E; Pope L; Crespo M; Miranda S; Attard G; Garrett MD; Clarke PA; Workman P; de Bono JS; Gore M; Kaye SB; Banerji U
Mol Cancer Ther; 2012 Jul; 11(7):1609-17. PubMed ID: 22556379
[TBL] [Abstract][Full Text] [Related]
19. Landscape of Phosphatidylinositol-3-Kinase Pathway Alterations Across 19 784 Diverse Solid Tumors.
Millis SZ; Ikeda S; Reddy S; Gatalica Z; Kurzrock R
JAMA Oncol; 2016 Dec; 2(12):1565-1573. PubMed ID: 27388585
[TBL] [Abstract][Full Text] [Related]
20. Activated phosphoinositide 3-kinase/AKT signaling confers resistance to trastuzumab but not lapatinib.
O'Brien NA; Browne BC; Chow L; Wang Y; Ginther C; Arboleda J; Duffy MJ; Crown J; O'Donovan N; Slamon DJ
Mol Cancer Ther; 2010 Jun; 9(6):1489-502. PubMed ID: 20501798
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
